bioject

  1. T

    Bioject Announces Results Of Intradermal Dose Sparing Influenza Study Conducted By Th

    Bioject Medical Technologies Inc. (OTCBB:BJCT), a leading developer of needle-free injection therapy systems (NFITS), announced that the Centers for Disease Control and Prevention (CDC) and its collaborating institutions presented the latest results of its clinical trial of the Biojector® 2000...
Back
Top